ArticleMolecular psychiatry2026
Higher peripheral blood homocysteine levels are associated with schizophrenia: evidence from a case-control study and a meta-analysis.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies suggest that homocysteine is associated with schizophrenia (SCZ), but existing evidence has been limited by small sample sizes. We aimed to investigate the association between blood homocysteine levels and schizophrenia. We conducted a case-control study followed by a meta-analysis. In the case-control study, 1159 patients with SCZ diagnosed according to DSM-5 (mean age 22.6 ± 8.4 years; 51.9% male) and 1440 healthy controls (HC) (mean age 38.4 ± 9.7 years; 51.3% male) were recruited. Plasma homocysteine levels were measured using an AU5800 automated biochemical analyzer and compared between groups. For the meta-analysis, PubMed, Embase, Cochrane Library, and Web of Science were systematically searched through February 2024 for case-control studies comparing blood homocysteine levels between patients with SCZ and HC. Ratios of means (RoM) with 95% confidence intervals were pooled using random effects models. In the case-control study, patients with SCZ had significantly higher homocysteine levels than HC (14.4 [11.3-21.6] vs. 12.3 [10.1-15.7] µmol/L; P < 0.001), and the association remained significant after adjustment for age and sex. Consistently, the meta-analysis of 54 case-control studies including 9781 participants (4526 patients with SCZ and 5255 HC) showed significantly higher homocysteine levels in patients with SCZ than in HC (RoM 1.34, 95% CI 1.28-1.41; P < 0.001). Subgroup analyses stratified by disease course, sample type, sex, study region, and homocysteine measurement method yielded consistent results. Blood homocysteine levels are elevated in patients with SCZ in both the case-control analysis and meta-analysis. These preliminary findings suggest a possible association between homocysteine and SCZ, although further well-controlled prospective and longitudinal studies are needed to clarify its clinical significance.
Identifiers
42773153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.